<?xml version="1.0" encoding="UTF-8"?>
<p>Many oral DMARDs have inherent antiviral activity and could be the treatment of choice for patients with coexisting immune-based diseases and infections. Especially when the infection is still in progression, choosing DMARDs with anti-microbial evidence would bring double benefits for better infection control without sacrificing underlying disease management. The antimicrobial mechanisms of DMARDs are often distinct from their immunomodulatory pathway, and the efficacy is different in viral species (
 <xref rid="table2-1759720X20947296" ref-type="table">Tables 2</xref>, 
 <xref rid="table3-1759720X20947296" ref-type="table">3</xref> and 
 <xref rid="table4-1759720X20947296" ref-type="table">4</xref>).
</p>
